Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorSPINI, Andrea
dc.contributor.authorCICCONE, Valerio
dc.contributor.authorROSELLINI, Pietro
dc.contributor.authorZICHE, Marina
dc.contributor.authorLUCENTEFORTE, Ersilia
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
dc.contributor.authorDONNINI, Sandra
dc.date.accessioned2022-12-16T14:46:10Z
dc.date.available2022-12-16T14:46:10Z
dc.date.issued2022-10-28
dc.identifier.issn2072-6694 (Print) 2072-6694 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171563
dc.description.abstractEnCancer is a clinical condition that can benefit from anti-angiogenic drugs (AADs). Given the low prevalence and the heterogeneity of childhood cancers, information about the safety of these drugs in pediatric patients is partially assessed. The aim of this study was to evaluate the safety of AADs in pediatric patients with solid tumors. Clinical trials and observational studies were searched in PubMed, ISI Web of Science, and ClinicalTrials database For each included study, adverse events (AEs) were extracted. A meta-analysis was conducted by pooling proportions of AEs using a random intercept logistic regression model. Seventy studies were retrieved. Most part were clinical trials (55 out of 70), and only fifteen observational studies were found. Overall, proportion of serious and non-serious AEs of AADs used as monotherapy was 46% and 89%, respectively. Proportions of serious AEs varied among drugs: sunitinib, 79%; lenvatinib, 64%; sorafenib, 48%; ramucirumab, 41%; pazopanib, 30%; and vandetanib, 27%. A higher proportion of non-serious hematological AEs was found in the patients receiving pazopanib with respect to sunitinib and lenvatinib. The safety profile of AADs has been extensively investigated for mostly drugs in phase I and II trials and is limited to acute toxicities. Overall, one out of two patients using AAD drugs in monotherapy experienced a serious AE despite proportions varied per single drugs. When AADs were combined with standard chemotherapy, the proportion of AEs varied in relation to the single combinations.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAnti-VEGF
dc.subject.enVegf inhibitors
dc.subject.enAntiangiogenic drugs
dc.subject.enPediatric
dc.subject.enChildren
dc.subject.enChildhood
dc.subject.enCancer
dc.subject.enTumor
dc.subject.enMeta-analysis
dc.subject.enSystematic review
dc.title.enSafety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/cancers14215315en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36358734en_US
bordeaux.journalCancersen_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue21en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03903758
hal.version1
hal.date.transferred2022-12-16T14:46:14Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2022-10-28&rft.volume=14&rft.issue=21&rft.eissn=2072-6694%20(Print)%202072-6694%20(Linking)&rft.issn=2072-6694%20(Print)%202072-6694%20(Linking)&rft.au=SPINI,%20Andrea&CICCONE,%20Valerio&ROSELLINI,%20Pietro&ZICHE,%20Marina&LUCENTEFORTE,%20Ersilia&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record